Cargando…

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis

OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP). METHODS: Cats ranged from 3.4–73 months of age (mean 13.6 months); 26 had effusive or dry-to-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Niels C, Perron, Michel, Bannasch, Michael, Montgomery, Elizabeth, Murakami, Eisuke, Liepnieks, Molly, Liu, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435921/
https://www.ncbi.nlm.nih.gov/pubmed/30755068
http://dx.doi.org/10.1177/1098612X19825701
_version_ 1783406725904203776
author Pedersen, Niels C
Perron, Michel
Bannasch, Michael
Montgomery, Elizabeth
Murakami, Eisuke
Liepnieks, Molly
Liu, Hongwei
author_facet Pedersen, Niels C
Perron, Michel
Bannasch, Michael
Montgomery, Elizabeth
Murakami, Eisuke
Liepnieks, Molly
Liu, Hongwei
author_sort Pedersen, Niels C
collection PubMed
description OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP). METHODS: Cats ranged from 3.4–73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusive disease. Cats with severe neurological and ocular FIP were not recruited. The group was started on GS-441524 at a dosage of 2.0 mg/kg SC q24h for at least 12 weeks and increased when indicated to 4.0 mg/kg SC q24h. RESULTS: Four of the 31 cats that presented with severe disease died or were euthanized within 2–5 days and a fifth cat after 26 days. The 26 remaining cats completed the planned 12 weeks or more of treatment. Eighteen of these 26 cats remain healthy at the time of publication (OnlineFirst, February 2019) after one round of treatment, while eight others suffered disease relapses within 3–84 days. Six of the relapses were non-neurological and two neurological. Three of the eight relapsing cats were treated again at the same dosage, while five cats had the dosage increased from 2.0 to 4.0 mg/kg q24h. The five cats treated a second time at the higher dosage, including one with neurological disease, responded well and also remain healthy at the time of publication. However, one of the three cats re-treated at the original lower dosage relapsed with neurological disease and was euthanized, while the two remaining cats responded favorably but relapsed a second time. These two cats were successfully treated a third time at the higher dosage, producing 25 long-time survivors. One of the 25 successfully treated cats was subsequently euthanized due to presumably unrelated heart disease, while 24 remain healthy. CONCLUSIONS AND RELEVANCE: GS-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.
format Online
Article
Text
id pubmed-6435921
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64359212019-04-15 Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis Pedersen, Niels C Perron, Michel Bannasch, Michael Montgomery, Elizabeth Murakami, Eisuke Liepnieks, Molly Liu, Hongwei J Feline Med Surg Original Articles OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP). METHODS: Cats ranged from 3.4–73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusive disease. Cats with severe neurological and ocular FIP were not recruited. The group was started on GS-441524 at a dosage of 2.0 mg/kg SC q24h for at least 12 weeks and increased when indicated to 4.0 mg/kg SC q24h. RESULTS: Four of the 31 cats that presented with severe disease died or were euthanized within 2–5 days and a fifth cat after 26 days. The 26 remaining cats completed the planned 12 weeks or more of treatment. Eighteen of these 26 cats remain healthy at the time of publication (OnlineFirst, February 2019) after one round of treatment, while eight others suffered disease relapses within 3–84 days. Six of the relapses were non-neurological and two neurological. Three of the eight relapsing cats were treated again at the same dosage, while five cats had the dosage increased from 2.0 to 4.0 mg/kg q24h. The five cats treated a second time at the higher dosage, including one with neurological disease, responded well and also remain healthy at the time of publication. However, one of the three cats re-treated at the original lower dosage relapsed with neurological disease and was euthanized, while the two remaining cats responded favorably but relapsed a second time. These two cats were successfully treated a third time at the higher dosage, producing 25 long-time survivors. One of the 25 successfully treated cats was subsequently euthanized due to presumably unrelated heart disease, while 24 remain healthy. CONCLUSIONS AND RELEVANCE: GS-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks. SAGE Publications 2019-02-13 2019-04 /pmc/articles/PMC6435921/ /pubmed/30755068 http://dx.doi.org/10.1177/1098612X19825701 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Pedersen, Niels C
Perron, Michel
Bannasch, Michael
Montgomery, Elizabeth
Murakami, Eisuke
Liepnieks, Molly
Liu, Hongwei
Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
title Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
title_full Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
title_fullStr Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
title_full_unstemmed Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
title_short Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
title_sort efficacy and safety of the nucleoside analog gs-441524 for treatment of cats with naturally occurring feline infectious peritonitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435921/
https://www.ncbi.nlm.nih.gov/pubmed/30755068
http://dx.doi.org/10.1177/1098612X19825701
work_keys_str_mv AT pedersennielsc efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis
AT perronmichel efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis
AT bannaschmichael efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis
AT montgomeryelizabeth efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis
AT murakamieisuke efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis
AT liepnieksmolly efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis
AT liuhongwei efficacyandsafetyofthenucleosideanaloggs441524fortreatmentofcatswithnaturallyoccurringfelineinfectiousperitonitis